Development of Novel Clinical Endpoints in Intermediate AMD

Exclusion Criteria

• •1. Media opacity or eye movement disorder (nystagmus) that interferes with retinal imaging data quality in the opinion of the investigator.
• •2. Severe ptosis, extraocular motility restriction or head tremor preventing adequate fundus visualization in the opinion of the investigator.
• •3. Any signs of nAMD or GA (does not apply to the late AMD group).
• •4. Any concurrent intraocular condition in the study eye (e. g. glaucoma or cataract) that, in the opinion of the investigator would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results.
• •5. Severe non-proliferative diabetic retinopathy, or proliferative diabetic retinopathy.
• •6. Any diabetic macular edema or macular disease
• •7. Ocular disorders in the study eye (i. e., pre-retinal membrane) at the time of enrolment that may confound interpretation of study results and compromise visual acuity.
• •8. Diagnosis of uncontrolled glaucoma with intraocular pressure of \>30 mmHg (despite current pharmacological or non-pharmacological treatment).
• •9. Known systemic illness which in the opinion of the investigator will prevent from actively participating in the study.
• •10. Concomitant treatment for AMD in either eye (concomitant use of vitamins/supplements is not excluded; does not apply to the late AMD group).
• •11. Any periocular or intravitreal injections (IVT) in either eye (does not apply to the late AMD group).
• •12. Participation in any other interventional trial.
• •13. Obvious retinal changes due to causes other than AMD (e.g. evidenced by an existing diagnosis of monogenetic macular dystrophies, Stargardt disease, cone rod dystrophy, or toxic maculopathies).
• •14. Any history of allergies to fluorescein.
• •Intermediate AMD
• •1. Any GA in the study eye
• •2. Any extrafoveal GA larger than 1.25 mm2 in the fellow eye.
• •Late AMD
• •Early AMD
• •1. Intermediate or late AMD (following Beckman classification) in any eye.
• •No AMD
• •1. Early to late AMD (following Beckman classification) in any eye.